Compare Adaptive Biotechnologies Corp (ADPT) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs SoFi Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.05 (market cap $3.33B), while SoFi Technologies Inc trades at $17.44 (market cap $22.77B). The key difference: SoFi Technologies Inc is far larger — about 6.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SOFI | |
|---|---|---|
Market Cap | $3.33B | $22.77B |
Sector | Health | Financials |
52-Week High | $22.37 | $32.21 |
52-Week Low | $10.24 | $15.15 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SOFI stock trades at $17.75, down 2.69% on the day, with a bullish technical signal and strong support at $17. The company reported revenue growth to $3.61B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion into small business loans and AI-driven products like Coach and Composer, aiming to deepen member engagement.
Outlook remains positive with a consensus price target of $21.22, offering 20% upside potential. Key risks include negative operating cash flow and high valuation multiples. Growth catalysts are centered on loan originations and ecosystem expansion, but investors should monitor execution and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
